Download PDF

1. Company Snapshot

1.a. Company Description

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States.The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.


The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases.It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc.The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017.


InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Show Full description

1.b. Last Insights on IFRX

Negative drivers behind InflaRx N.V.'s recent performance include the completion of a $30 million public offering of ordinary shares and pre-funded warrants, which may have led to dilution of existing shareholders. Additionally, the company's reliance on public offerings to raise capital may indicate a lack of confidence in its current financial position. Furthermore, the recent EC approval for GOHIBIC, although a positive event, may not have been enough to offset the negative sentiment surrounding the company's financial situation.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

InflaRx N.V. (IFRX) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa Transcript

Nov -10

Source: seekingalpha.com

Card image cap

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

Nov -10

Source: globenewswire.com

Card image cap

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Nov -07

Source: globenewswire.com

Card image cap

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Oct -21

Source: globenewswire.com

Card image cap

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep -12

Source: globenewswire.com

Card image cap

InflaRx Announces Participation in September Investor Conferences

Aug -21

Source: globenewswire.com

Card image cap

InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates

Aug -07

Source: zacks.com

Card image cap

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug -07

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Monoclonal Antibodies

Expected Growth: 8.5%

Growing demand for targeted therapies, increasing prevalence of inflammatory diseases, and advancements in biotechnology drive the monoclonal antibodies market growth.

7. Detailed Products

IFX-1

A first-in-class monoclonal anti-C5a antibody that targets the complement system, a key component of the innate immune system.

IFX-2

A monoclonal antibody that targets the C5a receptor, a key component of the complement system.

8. InflaRx N.V.'s Porter Forces

Forces Ranking

Threat Of Substitutes

InflaRx N.V. operates in the biotechnology industry, which is characterized by high research and development costs. The threat of substitutes is medium, as there are limited alternatives to the company's products, but the industry is constantly evolving, and new technologies could emerge as substitutes.

Bargaining Power Of Customers

InflaRx N.V. has a diverse customer base, including pharmaceutical companies, research institutions, and hospitals. The bargaining power of customers is low, as they rely on the company's products and services, and there are limited alternative suppliers.

Bargaining Power Of Suppliers

InflaRx N.V. relies on a network of suppliers for raw materials, equipment, and services. The bargaining power of suppliers is medium, as the company has some flexibility in choosing suppliers, but is also dependent on them for critical components.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market. The threat of new entrants is high, as new companies can emerge with innovative technologies and products, posing a threat to InflaRx N.V.'s market share.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. The intensity of rivalry is high, as companies compete for funding, talent, and market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 1.08%
Debt Cost 3.95%
Equity Weight 98.92%
Equity Cost 10.20%
WACC 10.13%
Leverage 1.09%

11. Quality Control: InflaRx N.V. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Sol-Gel Technologies

A-Score: 4.4/10

Value: 6.6

Growth: 3.7

Quality: 6.0

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Oxford Biomedica

A-Score: 3.7/10

Value: 6.4

Growth: 2.0

Quality: 3.1

Yield: 0.0

Momentum: 9.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
InflaRx

A-Score: 3.4/10

Value: 7.0

Growth: 5.9

Quality: 3.8

Yield: 0.0

Momentum: 3.5

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Exscientia

A-Score: 3.4/10

Value: 7.0

Growth: 2.2

Quality: 3.6

Yield: 0.0

Momentum: 4.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Moolec Science

A-Score: 3.1/10

Value: 7.8

Growth: 3.3

Quality: 2.5

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Affimed

A-Score: 2.2/10

Value: 8.2

Growth: 0.9

Quality: 4.2

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.06$

Current Price

1.06$

Potential

-0.00%

Expected Cash-Flows